Sir,
We read with interest two recent articles in the present journal focusing on escalation of carbapenamase-producing Enterobacteriaceae in the hospital environment, one from the Zhejing Province, China [1] , and another from Northern Italy [2] . Multidrug resistance is increasingly reported in clinical enterobacterial isolates in China. Not only resistance to carbapenems is on the rise, but in addition co-resistance to other clinically-relevant antibiotics such as fluoroquinolones, aminoglycosides and fosfomycin is increasingly observed. Polymyxins are therefore considered as last resort antibiotics for treating infections due to multidrug-resistant Gram negatives.
Recently, plasmid-mediated colistin resistance (MCR-1) was reported in enterobacterial from animals, food and patients from China [3] . Beyond China, the spread of the mcr-1 gene has been now reported worldwide in many enterobacterial species [4] . In addition, one of the major concern is the spread of carbapenem-and polymyxinresistant nosocomial Klebsiella pneumoniae isolates as observed in Italy [5] and more recently in France [6] . High plasmid-mediated mcr-1 carriage rate has been observed in E. coli collected from raw meat (15%) and animals (21%) in China, but not from inpatients (1%) [3] . Recently, a variant of MCR-1, namely MCR-2, has been reported from Belgium [7] .
Taking into account the wide spread MCR-1-producing strains in China and elsewhere, the diversity of genetic structures associated to the mcr-1 gene identified so far, and the diversity of the clonal backgrounds of the strains harboring that gene, it is likely that its spread does not correspond to a recent event in China.
We have performed a retrospective study to evaluate the occurrence of polymyxin resistance and of the Carbapenemase activity was assessed using the Rapidec Carba NP test (bioM erieux, La Balme-les-Grottes, France) [8] . Carbapenemase genes were searched as previously described [7] . All isolates were screened for polymyxin resistance by using the recently-developed Rapid Polymyxin NP test [9] . MICs of colistin and polymyxin B were determined by broth microdilution method as recommended by CLSI [10] . All polymyxin-resistant isolates were screened for the mcr-1 and mcr-2 genes by using PCR with primers mcr-all-F (5 0 -TATCGCTATGTGCTAAAG-3 0 ) and mcr-all-R (5 0 -TCTTGGTATTTGGCGGTA-3 0 ). All of 161 isolates were tested positive for the Rapidec Carba NP test. Further PCR and sequencing showed that all strains were positive for bla . No polymyxin-resistant isolate was detected using the Rapid Polymyxin NP test, and further determination of MICs of colistin and polymyxin B confirmed that all isolates were susceptible to polymyxins. Accordingly, all isolates tested negative for the mcr-1 and mcr-2 genes. This study revealed the absence of polymyxin-resistant isolate in our collection of carbapenemase-producing enterobacterial isolates. Combining with results obtained through other Chinese studies [4, 6, 8] , our data suggest that polymyxin resistance rates may be much lower than expected in Chinese hospitals. However, surveillance of polymyxin resistance shall be implemented on a regular basis to monitor its potential emergence in China.
To conclude, polymyxins might still constitute clinically-relevant options for treating infections caused by carbapenemase-producing Enterobacteriaceae in China. However, the use of polymyxins for humans is still not approved in China, considering its significant toxicity.
